Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who fully understand the trial and are willing to sign a consent form, attend all visits, and follow all study requirements.
• People who have been confirmed by pathology or tissue testing to have a B-cell blood cancer that is positive for the CD19 or CD20 protein, and whose cancer has returned or has not responded to previous treatment.
• People with one of these specific B-cell blood cancer types: B-cell acute lymphoblastic leukemia (B-ALL), a slower-growing B-cell lymphoma (such as CLL, FL, MZL, LPL, or HCL), or a faster-growing B-cell lymphoma (such as DLBCL, BL, or MCL).
• People with leukemia whose bone marrow tests show the cancer is still detectable or has returned; or people with lymphoma who have at least one tumor measuring 15mm or more, or two or more tumors each measuring at least 10mm.
• People whose general physical functioning is rated at 0, 1, or 2 on the ECOG scale, meaning they are able to carry out daily activities, possibly with some limitations (confirm with trial site).
• People whose cancer cells have tested positive for the CD19 or CD20 protein through laboratory testing.
• People whose doctors estimate they are likely to live for more than 3 months from the time of signing the consent form.
• People with relapsed or treatment-resistant B-cell leukemia who meet at least one of these conditions: the cancer returned within 6 months of first going into remission; the cancer never went into full remission after 2 rounds of standard chemotherapy; the cancer did not fully respond to or returned after further chemotherapy; or a stem cell transplant was not possible, was declined, or the cancer returned after one.
• People with relapsed or treatment-resistant B-cell lymphoma who meet at least one of the first four leukemia-related conditions listed above, and who have also previously received treatment with an anti-CD20 antibody drug and chemotherapy containing a specific class of drug called an anthracycline (confirm with trial site).

Who may not be able to join:

• People with certain heart conditions, including atrial fibrillation, a heart attack in the past 12 months, a heart rhythm disorder affecting the QT interval, reduced heart pumping function on ultrasound, significant fluid around the heart, or severe heart failure (NYHA class III or IV).
• People who currently have active graft-versus-host disease (a complication that can occur after a stem cell transplant).
• People with a history of severe lung disease.
• People who have another cancer that is at an advanced stage.
• People with a serious or ongoing infection that cannot be brought under control.
• People with a severe autoimmune disease or a serious condition affecting the immune system from birth.
• People with active hepatitis B or hepatitis C, where blood tests show the virus is active and liver function is abnormal.
• People with HIV or syphilis infection.
• People who have had a severe allergic reaction to a biological medicine, including antibiotics, in the past.
• People with certain neurological conditions that are not controlled, such as epilepsy, stroke-related brain injury, dementia, or cerebellar disease.
• People who are pregnant, breastfeeding, or planning to become pregnant within 12 months.
• People whose participation may increase health risks or affect the reliability of the trial results, as judged by the treating doctor.

Important: Always verify eligibility with the trial site directly before applying.